Product logins

Find logins to all Clarivate products below.


Chronic Heart Failure – Epidemiology – Epidemiology Dashboard

Clarivate Epidemiology’s coverage of heart failure (HF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the diagnosed event rates of AHF and the diagnosed prevalence of CHF for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the mature markets and Europe and 10 years for the other countries we cover.

All forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.

Clarivate Epidemiology’s HF forecast answers the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with severe disease?
  • Of all AHF hospitalization events, how many in each of the major mature pharmaceutical markets are drug-treated?
  • Of all people diagnosed with CHF, how many in each of the major mature pharmaceutical markets are drug-treated?
  • How will demographic trends such as population aging and improving life expectancy affect the epidemiology of HF over the forecast period?

In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following HF subpopulations:

  • Diagnosed AHF events by ejection fraction.
  • Diagnosed AHF events by treatment status.
  • Diagnosed AHF events by subpopulation.
  • Diagnosed CHF prevalent cases by severity.
  • Diagnosed CHF prevalent cases by treatment scheme.
  • Diagnosed CHF prevalent cases by ejection fraction.
  • Diagnosed CHF prevalent cases by comorbidity.

Note: Coverage may vary by country.

Related Market Assessment Reports

Report
Venous Thromboembolism – Current Treatment – Treatment Algorithms: Claims Data Analysis – Venous Thromboembolism (US)
Venous thromboembolism (VTE) is the obstruction of a vein caused by a thrombus. It consists of deep vein thrombosis (DVT) and pulmonary embolism (PE), depending on the vein affected. Current…
Report
Uterine Fibroids – Current Treatment – Treatment Algorithms: Claims Data Analysis – Uterine Fibroids (US)
Treatment for uterine fibroids includes pharmacological approaches and surgical procedures. NSAIDs help alleviate the pain but do not reduce the fibroids’ size. Progestins (e.g., norethindrone,…
Report
Biosimilars – Current Treatment – Oncology
In 2019, Amgen / Allergan’s trastuzumab biosimilar Kanjinti and bevacizumab biosimilar Mvasi were the first monoclonal antibody (MAb) biosimilars launched in the United States, followed by…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (Including IBS Without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by alterations in motility, stool consistency and frequency, and urgency. It is classified into three subtypes:…
Report
Kidney Transplant – Current Treatment – Treatment Algorithms: Claims Data Analysis – Kidney Transplant (US)
Each year in the United States, thousands of patients with end-stage renal disease undergo a kidney transplant. To prevent rejection and maintain the new kidney’s functionality, patients must…